source
- STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategyMedical mystery at the AHA conference: A Novartis drug lowered a risk marker for cardiovascular disease but did not lower chance of heart attack or stroke.
- FDA probes cancer risk from Zolgensma gene therapy after post-marketing tumor reportsThe FDA has issued a safety communication indicating it is investigating reports of malignancies in patients treated with Zolgensma, the adeno‑associated virus gene therapy for spinal muscular atro…